Fourteen-day infusion of ifosfamide in the management of advanced breast cancer refractory to protracted continuous infusion of 5-fluorouracil

Tumori

Volumn 87, Issue 1, 2001, Pages 27-29

  Di Lauro, V ^a   Spazzapan, S ^a   Lombardi, D ^a   Paolello, C ^a   Scuderi, C ^a   Crivellari, D ^a   Magri, M D ^a   Veronesi, A ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Advanced breast cancer; Chemotherapy; Continuous infusion; Ifosfamide

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; FLUOROURACIL; IFOSFAMIDE; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; FEMALE; HUMAN; INDWELLING CATHETER; LIVER METASTASIS; LUNG METASTASIS; NAUSEA; SEROSA; SOFT TISSUE SARCOMA; TREATMENT OUTCOME; VOMITING;

EID: 0035057088     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160108700107     Document Type: Article

References (9)

1. Pharmacokinetics, metabolism and clinical effects of ifosfamide in breast cancer patients
2. Use of ifosfamide in the management of breast cancer
3. Activity of ifosfamide in breast cancer
4. Feasibility trial of high-dose 7-day continuous infusion ifosfamide given on an outpatient basis
5. Ifosfamide bolus, followed by five-day continuous infusion in extensive pretreated patients with advanced breast cancer
6. A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients
7. Phase II study of ifosfamide and mesna in patients with metastatic breast cancer
8. Efficacy and tolerability of an ifosfamide continuous infusion in soft tissue sarcoma patients
9. Reporting results of cancer treatment